CervoMed Inc. - CRVO Total Company Value

Brandmark of cervomed.com (CRVO)

This price chart for CervoMed Inc. (CRVO) demonstrates a business valuation of 1.52. CervoMed Inc. (CRVO) possesses exceptional market influence due to the development of a unique treatment for Lewy body dementia. The current valuation relies on the promise of clinical trials, as the company has yet to launch profitable products. Management efficiency is achieved by outsourcing production and testing to external contractors.

CervoMed Corporation (CRVO) Total Company Value: for the period 11/23/2025 - 10/30/2026

CervoMed Inc. - analytical breakdowns and key metrics (CRVO)

- stock quotes and analyst forecast:
Price Performance Chart CervoMed, Inc.|CRVO - Consensus Target
- issuer market value details:
Market Value CervoMed|CRVO - Total Company Value
- business book valuation details:
Net Asset Value per Share CervoMed|CRVO - Company Book Value|Capitalization to Book Value Ratio cervomed.com|CRVO - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital CervoMed Inc.|CRVO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital cervomed.com|CRVO - Company Debts|Debt to Net Assets Ratio CervoMed|CRVO - Company Long-Term Debt|Short-Term Debt CervoMed|Quick Liquidity Indicator cervomed.com
- earnings and market multiples details:
CRVO - Net Profit
Analysis of all company metrics:CervoMed, Inc.
Manufactured product of CervoMed Inc.

The development of the innovative drug neflamapimod to combat dementia drives the investment attractiveness of CervoMed Inc. (CRVO). Business value is calculated by summing market capitalization and net debt, reflecting the actual price of a full company takeover. This metric allows for an assessment of the total cost to acquire all assets minus available cash. Historical extremes of this indicator signal either undervaluation or business degradation. An analysis of the enterprise value as of today helps determine the entry point prior to the release of Phase 2 data.

Competitors of CervoMed Inc. (CRVO)

Value Adjusted for Debt and Cash BIIB|NBIX: Real Price to Acquire Entire Company|RGC: Total Company Value|Axsome Therapeutics (AXSM) - Total Company Value|Total Enterprise Value acadia-pharm.com (ACAD)|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|AVXL (Anavex Life Sciences) - Enterprise Value|Real Price to Acquire Entire Company ceribell.com (CBLL)|Enterprise Value PRTA|ALEC - Total Enterprise Value|Total Company Value Annexon Inc. ANNX|Value Adjusted for Debt and Cash OMER|NGNE: Real Price to Acquire Entire Company|ACIU: Total Company Value|Voyager Therapeutics, Inc. (VYGR) - Total Company Value|Total Enterprise Value Neumora (NMRA)|Total Company Value Scilex Holding Co.|Real Price to Acquire Entire Company Tevogen Bio Inc. (TVGN)|Enterprise Value ACOG|CGTX - Total Enterprise Value|Enterprise Value IKT (Inhibikase Therapeutics, Inc.)|SAVA: Business Value|ASRT: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash COYA (Coya Therapeutics, Inc.)|VTGN: Enterprise Value|OVID - Company Buyout Price|Total Company Value Acumen Pharmaceuticals, Inc.|Business Value ATHE (Alterity Therapeutics Ltd)|Enterprise Value CLNN|Real Price to Acquire Entire Company pepgen.com PEPG|Jupiter Neurosciences - Real Price to Acquire Entire Company|Company Buyout Price relmada.com (RLMD)|Annovis Bio - Enterprise Value|Grace Therapeutics, Inc. (GRCE) - Real Price to Acquire Entire Company|Firefly Neuroscience Inc (AIFF) - Total Company Value|Klotho Neurosciences - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company NRSN|Total Company Value RVPH|Total Company Value MetaVia Inc (MTVA)|NRXS - Total Enterprise Value|Total Company Value Helius Medical Technologies HSDT|PASG: Business Value|Neuphoria - Enterprise Value|Total Enterprise Value minervaneurosciences.com|ATHA (Athira Pharma) - Real Price to Acquire Entire Company|Addex Therapeutics Ltd. (ADXN) - Enterprise Value|Total Company Value Alzamend Neuro Inc.|CYCN: Value Adjusted for Debt and Cash|Total Company Value Protagenic Therapeutics (PTIX)|KTTA - Total Enterprise Value|Enterprise Value CRGT (Cortigent)|ATXI - Real Price to Acquire Entire Company|Brainstorm Cell Therapeutics, Inc. - Enterprise Value|Total Enterprise Value Cara Therapeutics Inc|Chromocell Therapeutics (CHRO) - Total Company Value|Eliem Therapeutics Inc. - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company ITCI|Total Company Value LBPH|Total Company Value Marinus (MRNS)|NKGN - Total Enterprise Value|Total Company Value NeuroBo Pharmaceuticals NRBO|SAGE - Real Price to Acquire Entire Company|Synaptogenix - Enterprise Value|Total Enterprise Value Trevena Inc.|VIGL: Enterprise Value|Business Value WENA|Real Price to Acquire Entire Company CERE